StemTek Therapeutics Overview

  • Founded
  • 2013
Founded
  • Status
  • Private
  • Latest Deal Type
  • Accelerator/​Inc
  • Investors
  • 6

StemTek Therapeutics General Information

Description

Developer novel treatments designed for cancer targeting cancer stem cells. The company is accelerating drug discovery in cancer using cutting edge technology, world-class science, and a stem cell centric point of view for cancer therapy, enabling physicians to treat cancer.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • BIC BIZKAIA, Parque Tecnológico de Bizkaia
  • C/Astondo Bidea, s/n
  • 48160 Derio
  • Spain

StemTek Therapeutics Timeline

2017201820192020
Financing RoundFinancing Round
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

StemTek Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Accelerator/Incubator 12-Apr-2017 Completed Generating Revenue
2. Grant 12-Dec-2016 0000 Completed Generating Revenue
1. Early Stage VC 01-Jan-2016 Completed Startup
To view StemTek Therapeutics’s complete valuation and funding history, request access »

StemTek Therapeutics Executive Team (3)

Name Title Board Seat Contact Info
Angel Martin Ph.D Co-Founder, Chief Executive Officer & Chief Scientific Officer
To view StemTek Therapeutics’s complete executive team members history, request access »

StemTek Therapeutics Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
MassChallenge Accelerator/Incubator Minority 000 0000 000000 0
Horizon 2020 Government 000 0000 000000 0
Basque Venture Capital Management Venture Capital Minority 000 0000 000000 0
Bizkaia Seed Capital Venture Capital Minority 000 0000 000000 0
Helen (Finland) Corporation Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »